Gay CM(1), Stewart CA(1), Park EM(1), Diao L(2), Groves SM(3), Heeke S(1), Nabet BY(4), Fujimoto J(5), Solis LM(5), Lu W(5), Xi Y(2), Cardnell RJ(1), Wang Q(2), Fabbri G(6), Cargill KR(1), Vokes NI(1), Ramkumar K(1), Zhang B(1), Della Corte CM(7), Robson P(8), Swisher SG(9), Roth JA(9), Glisson BS(1), Shames DS(4), Wistuba II(5), Wang J(2), Quaranta V(3), Minna J(10), Heymach JV(1), Byers LA(11). Author information:
(1)Department of Thoracic/Head & Neck Medical Oncology, the University of Texas
MD Anderson Cancer Center, Houston, TX, USA.
(2)Department of Bioinformatics and Computational Biology, the University of
Texas MD Anderson Cancer Center, Houston, TX, USA.
(3)Department of Biochemistry, Vanderbilt University Medical Center, Nashville,
TN, USA.
(4)Department of Oncology Biomarker Development, Genentech Inc., South San
Francisco CA, USA.
(5)Department of Translational Molecular Pathology, the University of Texas MD
Anderson Cancer Center, Houston, TX, USA.
(6)AstraZeneca, Waltham, MA, USA.
(7)Department of Precision Medicine, Oncology Division, University of Campania
"Luigi Vanvitelli", Naples, Italy.
(8)The Jackson Laboratory for Genomic Medicine, Farmington, CT, USA.
(9)Department of Thoracic and Cardiovascular Surgery, the University of Texas MD
Anderson Cancer Center, Houston, TX, USA.
(10)Department of Internal Medicine and Simmons Cancer Center, the University of
Texas Southwestern Medical Center, Dallas, TX, USA.
(11)Department of Thoracic/Head & Neck Medical Oncology, the University of Texas
MD Anderson Cancer Center, Houston, TX, USA. Electronic address:
[Email]
